SCHEMBL253760

SCHEMBL253760

COc1ccc2cc(OC(C)=O)ccc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 2/20 0.65
ALDH1A1 P00352 1/20 0.65
F2 P00734 1/20 0.65
HPGD P15428 1/20 0.65
KDM4E B2RXH2 3/20 0.58
CA12 O43570 2/20 0.57
CA9 Q16790 2/20 0.57
CYP1A2 P05177 3/20 0.54
LMNA P02545 2/20 0.54
CYP3A4 P08684 2/20 0.54
POLB P06746 1/20 0.54
GAA P10253 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
NPC1 O15118 1/20 0.54
TP53 P04637 1/20 0.54
MAPT P10636 1/20 0.54
MAOA P21397 1/20 0.54
SLC6A2 P23975 1/20 0.54
RAB9A P51151 1/20 0.54
SLC6A3 Q01959 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14579660 0.96 GLA (0.61) GLAALDH1A1F2HPGDKDM4E
SCHEMBL12925820 0.96 GLA (0.61) GLAALDH1A1F2HPGDKDM4E
SCHEMBL14579657 0.96 GLA (0.61) GLAALDH1A1F2HPGDKDM4E
SCHEMBL30595409 0.91 CA12 (0.65) GLAALDH1A1F2HPGDKDM4E
SCHEMBL3974361 0.91 CA12 (0.65) GLAALDH1A1F2HPGDKDM4E
SCHEMBL5352558 0.87 CA12 (0.61) GLAALDH1A1F2HPGDKDM4E
SCHEMBL29705954 0.87 CA12 (0.61) GLAALDH1A1F2HPGDKDM4E
SCHEMBL20414569 0.87 AKR1C3 (0.60) GLAALDH1A1F2HPGDCYP1A2
SCHEMBL361383 0.83 LMNA (0.66) GLAALDH1A1F2HPGDLMNA
SCHEMBL30155392 0.83 KMT2A (0.61) GLAALDH1A1KDM4ECA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113308704-B Electrooxidation preparation method of naproxen intermediate 湖南大学 2022-04-08 CN claimed
CN-113308704-A Electrooxidation preparation method of naproxen intermediate 湖南大学 2021-08-27 CN claimed
US-8088150-B2 Device for disc shunt implantation and peri-shunt injection ALEEVA MEDICAL INC. (US) 2012-01-03 US claimed
US-20090198248-A1 Device for disc shunt implantation and peri-shunt injection YEUNG JEFFREY E 2009-08-06 US claimed
EP-1197227-B9 METHOD OF THE ADMINISTRATION OF DRUGS HAVING BINDING AFFINITY WITH PLASMA PROTEIN AND PREPARATION TO BE USED IN THE METHOD NIHON MEDIPHYSICS CO LTD (JP) 2008-06-11 EP claimed
EP-1197227-B1 METHOD OF THE ADMINISTRATION OF DRUGS HAVING BINDING AFFINITY WITH PLASMA PROTEIN AND PREPARATION TO BE USED IN THE METHOD NIHON MEDIPHYSICS CO LTD (JP) 2007-09-12 EP claimed
US-20230277504-A1 COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN ANTECIP BIOVENTURES II LLC 2023-09-07 US disclosed
US-20230266683-A1 ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS FUJIFILM BUSINESS INNOVATION CORP. (JP) 2023-08-24 US disclosed
US-20230266684-A1 IMAGE FORMING UNIT AND IMAGE FORMING APPARATUS FUJIFILM BUSINESS INNOVATION CORP. (JP) 2023-08-24 US disclosed
US-20230266684-A1 IMAGE FORMING UNIT AND IMAGE FORMING APPARATUS FUJIFILM BUSINESS INNOVATION CORP. (JP) 2023-08-24 US disclosed
US-20230266683-A1 ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS FUJIFILM BUSINESS INNOVATION CORP. (JP) 2023-08-24 US disclosed
CN-113308704-B Electrooxidation preparation method of naproxen intermediate 湖南大学 2022-04-08 CN disclosed
CN-113308704-B Electrooxidation preparation method of naproxen intermediate 湖南大学 2022-04-08 CN disclosed
US-20060223779-A1 Method of screening for inhibitors of human Fatty Acid-CoA Ligase 4 PRESCOTT STEPHEN M 2006-10-05 US disclosed
EP-1311660-A4 METHOD OF SCREENING FOR INHIBITORS OF HUMAN FATTY ACID-CoA LIGASE 4 UNIV UTAH RES FOUND (US) 2004-07-28 EP disclosed
EP-1311660-A1 METHOD OF SCREENING FOR INHIBITORS OF HUMAN FATTY ACID-CoA LIGASE 4 University of Utah Research Foundation (US) 2003-05-21 EP disclosed
WO-2002016575-A1 METHOD OF SCREENING FOR INHIBITORS OF HUMAN FATTY ACID-CoA LIGASE 4 UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2002-02-28 WO disclosed
EP-0759750-A4 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO HOWARD K (US) 1998-05-27 EP disclosed
EP-0759750-A1 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO, Howard, K. (US) 1997-03-05 EP disclosed
WO-1995031194-A1 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO HOWARD K (US) 1995-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277504-A1 COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN CYP2E1, CYP2D6, CYP3A43 GLA 3243/4885ALDH1A1 1027/4885F2 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.